Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of uproleselan plus chemotherapy versus placebo plus chemotherapy in relapsed or refractory acute myeloid leukemia
NL-OMON54661Phase 3Completed
- Sponsor
- GlycoMimetics
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Uproleselan + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: overall survival. Started Aug 2019; status: completed.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON54661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54661.